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Summary
Reducing insulin/IGF signaling allows for organismal survival during periods of inhospitable conditions by regulating the dia-
pause state, whereby the organism stockpiles lipids, reduces fertility, increases stress resistance, and has an increased life-
span. The Target of Rapamycin (TOR) responds to changes in growth factors, amino acids, oxygen tension, and energy sta-
tus; however, it is unclear how TOR contributes to physiological homeostasis and disease conditions. Here, we show that
reducing the function of Drosophila TOR results in decreased lipid stores and glucose levels. Importantly, this reduction
of dTOR activity blocks the insulin resistance and metabolic syndrome phenotypes associated with increased activity of
the insulin responsive transcription factor, dFOXO. Reduction in dTOR function also protects against age-dependent decline
in heart function and increases longevity. Thus, the regulation of dTOR activity may be an ancient ‘‘systems biological’’
means of regulating metabolism and senescence, that has important evolutionary, physiological, and clinical implications.Introduction
The major cause of metabolic syndrome (defined as a cluster of
metabolic abnormalities such as elevated glucose and lipid
levels, related to a state of insulin resistance) and diabetes in
humans is reduction of insulin signaling, but the underlying
pathways and mechanisms are not completely understood.
Likewise, caloric excess can lead to nutrient toxicity and desen-
sitization of insulin signaling. Thus, dysregulation of energy
homeostasis can lead to metabolic disturbances and predispo-
sition to a variety of endocrine diseases including diabetes, car-
diovascular disease, and cancer (Biddinger and Kahn, 2006;
Kahn et al., 2005; Lee and White, 2004).
One major system that regulates energy homeostasis in
higher metazoa is the insulin/IGF pathway. The functionally con-
served components of the insulin/IGF pathway like insulin, the
insulin receptor (InR), insulin receptor substrate (IRS), phosphoi-
nositide 3-kinase (PI3K), protein kinase B (PKB, a.k.a. Akt) and
the forkhead transcription factor FOXO have been shown to
be involved in glucose and lipid homeostasis (Accili and Arden,
2004; Barthel et al., 2005; Biddinger and Kahn, 2006; Kahn et al.,
2005; Lee andWhite, 2004) as well as growth and aging (Burger-
ing and Kops, 2002; Finch and Ruvkun, 2001; Greer and Brunet,
2005; Kenyon, 2005; Tran et al., 2003). Loss of insulin signaling
in the periphery and in pancreatic b cells can lead to hyperglyce-
mia and diabetes (Biddinger and Kahn, 2006; Lee and White,
2004). For example, disruption of the InsR gene in the pancreatic
b cells reduces islet size and insulin secretion (Kulkarni et al.,
1999). IRS1 knockout mice are hyperglycemic, but their pancre-
atic b cells hypertrophy to compensate for increased peripheral
insulin resistance (Araki et al., 1994; Burks and White, 2001).
In contrast, IRS2 knockout mice are diabetic because theirCELL METABOLISM 4, 133–142, AUGUST 2006 ª2006 ELSEVIER INC.pancreatic b cells are absent due to increased cell death (Burks
and White, 2001). Additionally, systemic loss of insulin signaling
inmetazoans leads to elevated lipids as seen in theDaf-2mutant
worms, Chico/IRS mutant flies, and IRS2 ablated mice (Bo¨hni
et al., 1999; Burks et al., 2000; Kenyon et al., 1993; Kimura
et al., 1997).
Many of these insulin/IGF-mediated metabolic effects de-
pend on the winged helix transcription factor, FOXO. FOXO
was first identified in the worm,C. elegans asDaf-16, a mutation
that can suppress the increased lipid levels and longevity
caused by loss of Daf-2, the worm InR ortholog (Lin et al.,
1997; Ogg et al., 1997). There is a single evolutionarily con-
served Drosophila FOXO ortholog (Junger et al., 2003; Kramer
et al., 2003; Puig et al., 2003) and threemammalian FOXO genes
(FOXO1, FOXO3a, and FOXO4). FOXO1 controls glucose ho-
meostasis in both peripheral tissues and pancreatic b cells (Ac-
cili and Arden, 2004). For example, expression of a constitutively
activated FOXO1 (resistant to insulin/IGF-mediated inactivation)
in liver and pancreatic b cells causes hepatic insulin resistance
and loss of pancreatic b cells via increased apoptosis, whereas
reduction of FOXO1 function can reverse the loss of pancreatic
b cells and hyperglycemia seen in the IRS2 ablated mice (Kita-
mura et al., 2002; Nakae et al., 2002). Thus, FOXO is a critical
mediator of insulin signaling in both insulin sending and receiv-
ing tissues.
The Tuberous Sclerosis Complex (TSC1-2)/Target of Rapa-
mycin (TOR) pathway responds to changes in insulin/IGF levels,
amino acid levels, energy charge, lipid status, mitochondrial
metabolites, and oxygen tension by adjusting cell growth
(Abraham, 2002; Fingar and Blenis, 2004; Kim and Sabatini,
2004; Kozma and Thomas, 2002; Long et al., 2004; Oldham
and Hafen, 2003; Wullschleger et al., 2006). In addition to itsDOI 10.1016/j.cmet.2006.05.013 133
A R T I C L Ewell-defined role in controlling cell growth, the TSC1-2/TOR
pathway may also potentially be a critical regulator of glucose
and lipid homeostasis as TSC1-2/TOR signaling functionally in-
teracts with the insulin/IGF pathway. A role for TOR signaling in
glucose and lipid homeostasis in mammalian systems is dem-
onstrated by the S6K1 knockout mice. Thesemice are hypergly-
cemic caused by diminished insulin secretion due to reduced
pancreatic b cell mass (Pende et al., 2000; Um et al., 2004).
This result is in keeping with studies that show that rapamycin
treatment leads to decreased levels of translation, growth, and
survival of pancreatic b cells (Bell et al., 2003; Kwon et al.,
2004; McDaniel et al., 2002). However, the mS6K1 mutant
mice have low lipid levels because of adipocytes that have in-
creased fatty acid b-oxidation. Additionally, the mS6K1 mutant
mice show enhanced glucose uptake upon exogenous insulin
addition due to insulin hypersensitivity in peripheral tissues via
loss of a negative feedback loop on IRS (Um et al., 2004).
Thus, TOR signaling via S6K can modulate insulin sensitivity
by altering Ser307 and Ser636/639 phosphorylation and IRS
protein levels (Carlson et al., 2004; Haruta et al., 2000; Patti
et al., 1998; Tremblay et al., 2005; Tzatsos and Kandror, 2006;
Ueno et al., 2005; Um et al., 2004).
There are additional levels where TSC1-2/TOR signaling may
positively and negatively regulate insulin signaling. There are
data that suggest that the IRS Ser302 site is required for
signaling to TOR and S6K (Giraud et al., 2004). Thus, ser/thr
phosphorylation of the IRS proteins may mediate both positive
and negative signals for energy homeostasis. Furthermore,
Akt/PKB activity may also be directly regulated by the nutrient-
sensitive TOR pathway. Although the insulin/IGF pathway can
signal to the TSC1-2/TOR pathway, recent evidence suggests
that TOR may directly control Akt/PKB function because Akt/
PKB activation depends on TORC2 complex-specific TOR
Ser473 phosphorylation of Akt/PKB (Sarbassov et al., 2005).
Thus, these studies suggest that dysregulation of TSC1-2/
TOR signaling may contribute to the pathological progression
of metabolic syndrome and diabetes, yet the direct role and
function of TOR is unclear in this context.
Another functionally conserved energy homeostatic pathway
is the AMPK pathway. This pathway responds to altered energy
states caused by cellular stresses like mitochondrial dysfunc-
tion, anti-diabetic drugs, and exercise (Carling, 2004; Hardie,
2005; Kahn et al., 2005). Activation of the energy sensing
AMPK pathway by activated AMPK as well as metformin or AI-
CAR treatment results in decreased lipogenesis and gluconeo-
genesis via both central and peripheral effects (Carling, 2004;
Hardie, 2005; Kahn et al., 2005). Activated AMPK can phosphor-
ylate TSC2, which inhibits TOR signaling, while loss of AMPK ac-
tivity causes an increase in TOR signaling (Bolster et al., 2002;
Dubbelhuis and Meijer, 2002; Inoki et al., 2003; Kimura et al.,
2003; Shaw et al., 2004). However, the requirement of TOR func-
tion for the AMPK energy response is not known. These effects
may also be mediated by targets including glycogen synthase,
hormone-sensitive lipase, acetyl-CoA carboxylase-2, HMG-
CoA reductase, p300, and p53 (Carling, 2004; Hardie, 2005;
Kahn et al., 2005); the different roles of these proteins in the
AMPK-mediated low energy response are not well known. Fur-
thermore, activation of AMPK leads to IRS Ser-789 phosphory-
lation and enhancement of insulin signaling, which suggests that
the AMPK response can act separately from the TORpathway to
enhance insulin signaling (Jakobsen et al., 2001). Clearly, there134is a great need to understand the regulation of TSC1-2/TOR sig-
naling as it relates to the maintenance of energy homeostasis
because TOR function is implicated in both insulin/IGF and
AMPK signaling.
Although TOR occupies a central node that governs catabolic
or anabolic responses to different nutritional and energy states,
the resultant metabolic effects of altering TOR function in
a metazoan are incompletely and poorly understood. This study
examines in detail the function ofDrosophila TOR in terms of en-
ergy homeostasis and senescent responses. We show that re-
duction of dTOR function results in decreased glucose and lipid
levels with concomitant increase of DILP2 from the insulin pro-
ducing cells. We also show that a reduction of dTOR function
can block activated dFOXO-mediated insulin resistance and
metabolic syndrome phenotypes. Taken together, these data in-
dicate that dTOR function is required for the maintenance of en-
ergy homeostasis and organismal senescence. The additional
ramifications of this study are that reduction of TOR function
may have clinical utility for treating metabolic syndrome and in-
sulin resistance.
Results
Discovery and analysis of a novel dTOR allele
Complete loss of dTOR function results in early larval lethality
(Oldham et al., 2000; Zhang et al., 2000). In order to analyze
the effects of a reduction of dTOR function on processes like en-
ergy homeostasis and senescence, we utilized a new hypomor-
phicmutation in dTORwithin the kinase domain (Figure 1A) (Old-
ham et al., 2000). Flies transheterozygous for this dTOR allele
(dTOR2L7) and a dTOR P-element insertion (dTORl(2)k17004, here-
after called dTOR7/P mutant) are viable and 20% smaller com-
pared to control (data not shown). We first examined how
dTOR effectors are altered in the dTOR7/P mutant. Unexpect-
edly, we observed no d4EBP protein in the dTOR7/P mutant
and only mildly decreased phospho-dS6K compared to the
control (Figure 1B). This effect may be due to translational or
post-translational effects, as we observe d4EBP mRNA in the
dTOR7/P mutant (data not shown).
Reduction of dTOR function decreases lipid levels
Depending on the type of environmental perturbation, lipid
levels may be increased for diapause (as seen in InR pathway
mutants) or hibernation, whereas during times of energy reduc-
tion caused by dieting or exercising (which leads to AMPK acti-
vation), lipids are mobilized preferentially over protein stores for
fuel because of their high energy content (Cahill and Veech,
2003; Saltiel and Kahn, 2001). We first determined how meta-
bolic stores are altered by examining the lipid levels in the
dTOR7/P mutant. We see that reduction of dTOR function by
the dTOR7/P mutant causes a decrease in lipid levels in the fat
body. Nile Red staining of the dTOR7/P mutant revealed sub-
stantially decreased lipid levels in the fat body compared to con-
trol (Figures 1C and 1D). The remaining lipids were confined to
small vesicles within the cytoplasm of the fatbody cells.
These decreased lipid levels in the dTOR7/P mutant may be
due to an increased utilization of lipids from pre-existing lipid
stores and/or the prevention of lipid storage. This decrease in
lipid levels correlated with an increase in the mRNA levels of a li-
pase (termed Brummer inDrosophila) involved in regulating lipid
levels in the fatbody (Gro¨nke et al., 2005), which suggests thatCELL METABOLISM : AUGUST 2006
TOR couples energy homeostasis to senescenceFigure 1. Drosophila TOR regulates lipid metabolism
A) Sequence alignment of the dTOR7 allele. The mutated residue is D2116G and is completely conserved in TOR orthologs (indicated by the line). This residue lies in the N-
terminal region of the kinase domain and shows reduced kinase activity (unpublished data).
B) Slightly reduced phospho-dS6K (T398) and no wild-type d4EBP levels in the dTOR7/Pmutant flies compared to control as determined by Western blotting. Actin levels
are on the bottom.
C) Nile Red staining of control third instar larvae fatbody.
D) Nile Red staining of the dTOR7/P mutant larvae fatbody. DNA stained with DAPI.
E) Reduction of dTOR function results in increased lipase mRNA levels.
F) Reduction of dTOR function results in elevated ketone bodies (p = .0028, unpaired, two-tailed t test). Experiment has been performed two times independently.reduction of dTOR function results in lipid breakdown due to in-
creased lipase activity (Figure 1E). Consistent with the elevated
lipase mRNA levels, we also observed a 27% decrease in tri-
glyceride levels in the dTOR7/P mutant that depended on the li-
pase gene as a null mutant for brummer reversed the triglyceride
decrease (data not shown). To further determine the basis of the
lipid breakdown, we measured ketone bodies (b-hydroxybuty-
rate), whose levels also serve as an indicator of lipid utilization.
The data show that there is a 155% increase in b-hydroxybuty-
rate levels in the dTOR7/P mutant flies, which is consistent with
a conversion of lipids to ketone bodies (Figure 1F). Thus, reduc-
tion of dTOR function causes the breakdown of lipid stores and
conversion into ketone bodies.
Inhibition of dTOR activity lowers glucose levels
Changes in lipid metabolism are linked with alterations in insulin
signaling (Saltiel and Kahn, 2001). There are 7 insulin-like pep-
tides in Drosophila (DILPs), which are structurally and function-
ally related to insulin and IGF (Brogiolo et al., 2001). The bilateral
set of sevenmedial neurosecretory insulin producing cells (IPCs)
in the fly brain hemispheres express DILP2 (Ikeya et al., 2002;
Rulifson et al., 2002). Loss of the IPCs increase blood glucose
levels and can be rescued by exogenous DILP2 expression,
which shows that loss of insulin/IGF production and signaling
is causally linked to altered glucose homeostasis in Drosophila
(Broughton et al., 2005; Ikeya et al., 2002; Rulifson et al.,
2002). As DILP2 is a key regulator for glucose levels, we first de-
terminedwhether DILP2 protein levels are changed in the neuro-
secretory IPCs in the dTOR7/P mutant. We see that the dTOR7/P
mutant results in an increase in DILP2 protein levels in both the
cell body and axonal projections of the IPCs (Figures 2A andCELL METABOLISM : AUGUST 2006Figure 2. Drosophila TOR regulates DILP2 levels and glucose homeostasis
A) DILP2 shows expression in the cytoplasm of the NSC cell body and into the
axonal processes in the wild-type.
B) The dTOR7/P mutant has increased DILP2 staining in both the cell body and
axons. Confocal Z-series taken at 603.
C) DILP2 mRNA levels in the dTOR7/P mutant. DILP2 (top) mRNA levels are
increased in the dTOR7/P mutant flies. Actin loading control is on the bottom.
D) The dTOR7/P mutant glucose levels are significantly decreased (p = .0086,
unpaired, two-tailed t test) compared to control. Experiment has been performed
three times independently.135
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ducing dTOR function also occurs at the mRNA level, we per-
formed RT-PCR on the dTOR7/Pmutant and looked for changes
in DILP2 mRNA levels. Remarkably, we saw that the dTOR7/P
mutant had increased DILP2 mRNA levels relative to the control
(Figure 2C). Thus, reducing dTOR function can increase the
levels of DILP2. As altered DILP2 levels lead to changes in glu-
cose homeostasis, we next examined the dTOR7/P mutant for
possible effects on glucose homeostasis. Remarkably, the
dTOR7/P mutant shows a 39% decrease in blood glucose levels
(Figure 2D). Thus, a reduction of dTOR function can lead to low-
ered glucose levels.
Lowering dTOR function blocks activated FOXO-
mediated insulin resistance
The insulin/IGF pathway is a major integrator of metabolic and
stress signals that depend on the function of FOXO (Matsumoto
and Accili, 2005). Constitutively activated FOXO can increase
the lifespan of worms and flies if expressed in appropriate spa-
tiotemporal patterns (Giannakou et al., 2004; Hwangbo et al.,
2004; Libina et al., 2003; Wolkow et al., 2000). However, consti-
tutive FOXO activation in the liver and pancreatic b cells causes
hyperglycemia in mammals (Nakae et al., 2002). Thus, activated
FOXO represents themost distal step known for inducing insulin
resistance and metabolic syndrome phenotypes.
Because decreased TOR signaling can enhance insulin sig-
naling upstream of FOXO via reduced IRS ser/thr phosphoryla-
tion, we used a constitutively active dFOXO (dFOXO-TM, in
which the three Akt/PKB phosphorylation sites have been inac-
tivated) to ask whether reducing dTOR function can act down-
stream of dFOXO function (Hwangbo et al., 2004; Junger
et al., 2003; Kramer et al., 2003; Puig et al., 2003). We first ana-
lyzed systemic dFOXO expression for changes in lipid and glu-
cose levels. We see that expression of activated dFOXO results
in increased lipid levels as assessed by Nile Red staining and
measurement of triglyceride levels (Figures 3A–3C. Compare
to Figures 1A and 1B). These elevated lipid levels correspond
with increased dFAS mRNA levels in this background
(Figure 3D). We next asked whether the dTOR7/P mutant is
able to alter this activated dFOXO metabolic phenotype. We
see that reduction of dTOR function can block both the lipid
and glucose increase mediated by constitutively activated
dFOXO (Figure 3C and data not shown). We also see that
dFAS mRNA levels are decreased in the activated dFOXO-
dTOR7/P mutant background (Figure 3D). We see that dFOXO
is still present in the nucleus so the dTOR7/P mutant is not alter-
ing the localization of dFOXO (data not shown). As activated
dFOXO expression in the head fatbody decreases DILP2
mRNA levels (Hwangbo et al., 2004), we next determined the ef-
fect of expressing activated dFOXO specifically in the IPCs. We
see that activated dFOXO-mediated insulin resistancewithin the
IPCs leads to low DILP2 mRNA levels and high glucose levels
(Figures 3E and 3F). Remarkably, the low DILP2 mRNA levels
and high glucose levels caused by constitutively activated
dFOXO expression in the insulin producing cells are blocked
by the dTOR7/P mutant (Figures 3E and 3F). Thus, in addition
to upstream effects on insulin pathway components, reducing
dTOR function can block dFOXO-mediated relevant metabolic
targets to reverse the increased glucose and lipid phenotypes
(Figure 4).136Dampening dTOR signaling enhances lifespan and heart
performance
As TOR integrates growth factor signaling, amino acids levels,
energy charge, lipid status, mitochondrial metabolites, and oxy-
gen tension, TOR responds to many stimuli that can potentially
affect both longevity and organ senescence (Kenyon, 2005;
Partridge and Gems, 2002; Sharp and Bartke, 2005; Tatar et al.,
Figure 3. Reducing TOR activity blocks activated FOXO-mediated insulin resis-
tance and metabolic syndrome phenotypes
A) Nile Red staining of arm-Gal4; UAS-dFOXO-TM third instar larvae fatbody.
B) Nile Red staining of the arm-Gal4, dTOR7/P; UAS-dFOXO-TM third instar larvae
fatbody.
C) The triglyceride assay shows that the arm-Gal4; UAS-dFOXO-TM line has in-
creased lipid levels, while the arm-Gal4,dTOR7/P; UAS-dFOXO-TMmutant combi-
nation has lipid levels similar to the dTOR7/P single mutant.
D) Reduction of dTOR function reverses the dFOXO-TM-mediated increase in
dFAS mRNA levels.
E) The glucose assay shows that the DILP2-Gal4; UAS-dFOXO-TM line has in-
creased glucose levels, while the DILP2-Gal4,dTOR7/P; UAS-dFOXO-TM mutant
combination has glucose levels similar to the dTOR7/P single mutant. Fold change
in triglyceride or glucose levels where 1 equals wild-type triglyceride or glucose
levels, >1 equals increased triglyceride or glucose levels, and <1 equals reduced
triglyceride or glucose levels. All lines are significantly different (p < .05, unpaired,
two-tailed t test) relative to the control.
F) Decreasing dTOR activity overcomes dFOXO-TM-mediated inhibition of DILP2
mRNA levels.
All experiments have been performed twice independently.CELL METABOLISM : AUGUST 2006
TOR couples energy homeostasis to senescenceFigure 4. Model of functional interaction of TOR sig-
naling with the insulin/IGF pathway
The numbered arrows indicate potential levels of
functional interaction and are neither meant to
represent whether the interaction is positive or nega-
tive nor any hierarchal dominance. TORC2 is not
included.2003). Indeed, studies in Drosophila using overexpression of
dTOR pathway inhibitors suggest that TOR signaling may be
contributing to aging (Kapahi et al., 2004). Furthermore, direct
inhibition of TOR in yeast and the worm shows that loss of TOR
function results in increased lifespan alongwith increased stress
resistance (Kaeberlein et al., 2005; Powers et al., 2006; Vellai
et al., 2003). We asked whether the dTOR7/P mutant could alter
aging at the organ and organismal level, by first using an assay
that measures the progressive age-dependent decline in heart
function (Wessells et al., 2004). We found that the dTOR7/P mu-
tant had a low heart failure rate that was observed in young flies
as well as old flies (Figure 5A). Remarkably, the heart failure rate
of old dTOR7/Pmutant flies was similar to the heart failure rate of
the young flies. Furthermore, in keeping with the decrease in
heart failure, the median lifespan of the dTOR7/P mutant was in-
creased by 20% under normal feeding conditions (Figure 5B).
Thus, the age-related protection of heart function correlates
well with the increased lifespan in the dTOR7/P mutant.
As increased longevity is frequently associatedwith increased
stress resistance (Kenyon, 2005),we testedwhether thedTOR7/P
mutant can resist environmental stresses. We first tested the
ability of the dTOR7/Pmutant to withstand water-only starvation.
Remarkably, the dTOR7/Pmutant had no difference in the ability
to withstand water-only starvation (Figure 5C). We next tested
dTOR7/P for its ability to resist ROS production induced by para-
quat treatment. Again, dTOR7/P behaved essentially as wild-
type when subjected to oxidative stress (Figure 5D). Thus, re-
duction of dTOR function does not provide resistance against
acute stresses. We also observed that the dTOR7/P mutants
are fertile, have wild-type levels of ATP, and retain flight ability
(data not shown). Despite the strong association between in-
creased longevity and acute stress resistance, these results
suggest that a partial reduction in dTOR function may preferen-
tially regulate organ senescence and longevity versus acute
stress responses.
Discussion
TOR controls multiple aspects of lipid metabolism
In contrast to the elevated lipid levels caused by reduction
of systemic insulin signaling (Bo¨hni et al., 1999; Burks et al.,
2000; Kenyon et al., 1993; Kimura et al., 1997), the dTOR7/PCELL METABOLISM : AUGUST 2006Figure 5. Drosophila TOR regulates aging and organ senescent responses
A) dTOR regulates age-related changes in cardiac performance. Failure rate of
wild-type flies (yw) changes significantly with age (age-by-genotype, c2 = 59.2,
p < .0001). The cardiac failure rate of the dTOR7/P mutant exhibited a significantly
decreased rate of change with age compared to yw (age-by-genotype, c2 = 7.49,
p = .0519). Numbers tested are as follows: yw 1 week = 100, 2 week = 47, 4 week =
79, 5 week = 92. dTOR7/P mutant 1 week = 245, 2 week = 231, 4 week = 177,
5 week = 200.
B) The dTOR7/P mutant flies exhibited a significantly extended lifespan as com-
pared to the yw background (c2 = 12.42, p = .0004) and to the dTOR7/Pmutant flies
which also carried a genomic rescue construct for dTOR (c2 = 10.56, p = .0012).
The dTOR7/Pmutant flies with a dTOR rescue construct no longer showed a signif-
icant difference from the yw background (c2 = .15, p = .7001). Numbers tested
were as follows: yw = 59, yw + dTOR rescue construct = 59, dTOR7/Pmutant = 88.
C) Reduction in dTOR activity has no effect on starvation resistance. The dTOR7/P
mutant does not affect resistance to starvation conditions compared to the back-
ground yw genotype (genotype effect, c2 = 1.23, p = .2676). Representative results
from one of two replicate experiments are shown. Numbers tested for this replicate
are: yw = 31, dTOR7/P mutant = 38.
D) Reduction in dTOR activity has no effect on resistance to oxidative stress. The
dTOR7/Pmutant had no significant effect on survival compared to the background
yw stock (unpaired, two-tailed t test, p = .477). Representative results from one
of two replicate experiments are shown. Numbers tested for this replicate
are: yw = 28, dTOR7/P mutant = 16.137
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dTOR7/P mutant shows decreased lipid levels of the fat body
that depend on the function of a lipase involved in lipid metabo-
lism (Gro¨nke et al., 2005). We also observed elevated ketone
bodies in the hypoglycemic dTOR7/Pmutant, which is indicative
of the increased utilization of lipids. Studies in mammalian car-
diac tissue have shown that ketone bodies provide their high en-
ergy electrons directly to complex I, the NADH dehydrogenase
multienzyme complex, of the mitochondrial electron transport
chain (Cahill and Veech, 2003). Thus, the altered lipid levels
show that dTOR has a critical role in determining the fate of fats.
It has also been shown that d4EBP is involved in lipid metab-
olism because the increased lipid levels caused by rapamycin
treatment are blocked by a d4EBP mutant (Teleman et al.,
2005a). Furthermore, loss of the melted mutant has lower lipid
levels, due to lowered triglyceride production (Teleman et al.,
2005b). This effect is due to increased d4EBP protein levels via
dFOXO activation in the fatbody. However, there is no change
in glucose levels. In this respect, the melted mutant resembles
the FIRKO mouse because it shows decreased triglyceride
levels without a change in glucose levels (Biddinger and Kahn,
2006). We see that the dTOR7/Pmutant has a different lipid phe-
notype than the one caused by rapamycin treatment, which sug-
gests that rapamycin alters dTOR function in a different manner
than the dTOR7/Pmutant. Additionally, we see that a novel hypo-
morphic dTOR FAT domain allele in combination with the dTORP
allele also shows low glucose and lipid levels (data not shown),
which suggests that partial reduction of dTOR activity repre-
sents a unique phenotypic class of dTOR metabolic effects ver-
sus an allele specific phenotype. Although rapamycin affects
TORC1 directly, TORC2 may be altered indirectly via TOR
depletion and blocking of TORC2 assembly (Sarbassov et al.,
2005, 2006). Thus, it is not currently clear if the effects of rapa-
mycin are due to inhibiting TORC1 and/or TORC2. It is known
that rapamycin can impair pancreatic b cell function because
it causes decreased growth and survival (Bell et al., 2003;
Kwon et al., 2004; McDaniel et al., 2002). Thus, rapamycin treat-
ment can lead to elevated glucose and lipid levels, possibly as
a result of systemic insulin loss (Morrisett et al., 2003).
TOR is required for glucose homeostasis
Wesee thatDILP2 levels are increased in the IPCsof thedTOR7/P
mutant and that the dTOR7/Pmutant has lowered glucose levels.
Thus, reduction of dTOR function can lead to increased DILP2
levels and a reduction of glucose levels. Recent studies with
the Drosophila miRNA-278 mutant also showed elevated DILP
levels, yet displayed fatbody-mediated insulin resistance as
shown by elevated d4EBP and glucose levels (Teleman and
Cohen, 2006). We believe that the dTOR7/P mutant represents
an insulin-sensitized state because the dTOR7/P mutant shows
decreased levels of the insulin resistance marker d4EBP, the
dTOR7/P mutant shows decreased glucose levels, and, as dis-
cussed below, the dTOR7/P mutant blocks activated dFOXO-
mediated insulin resistance phenotypes. Thus, the dTORmutant
phenotype resembles a whole-animal ‘insulin-sensitized’ state
that can function below the level of constitutive dFOXO activity.
TOR signaling integrates with the insulin pathway
at multiple levels
We see that overexpression of activated dFOXO in peripheral
and IPC tissues results in elevated glucose and lipid levels. Al-138though dTOR signaling can alter insulin signaling upstream of
dFOXO, reducing dTOR function is able to reverse these effects.
Thus, our results show that reduction of dTOR activity can block
the activated dFOXO-mediated insulin resistance andmetabolic
syndrome phenotypes (Figure 4). These results suggest that
strategies to dampen, reduce, or block TOR signaling may be
able to overcome insulin resistance (i.e., hyperglycemia and hy-
pertriglyceridemia) below the level of increased FOXO activity in
mammalian systems.
Although FOXO has >100 potential targets that might contrib-
ute to the metabolic phenotype (Lee et al., 2003; McElwee et al.,
2003; Murphy et al., 2003), we have identified dFAS and DILP2
as candidate mediators of the dTOR effect on the dFOXO met-
abolic phenotypes. The effect on dFAS is interesting because it
is upregulated by dFOXO overexpression and in an IRS/chico
mutant (data not shown) and may be an important determinant
of the lipid levels. It has also been shown that activation of
daf-16/FOXO can decrease the mRNA levels of a worm insulin
gene, ins-7 (Murphy et al., 2003). This result is consistent with
our results showing that DILP2 mRNA levels are decreased
and reducing dTOR activity can reverse this dFOXO-mediated
reduction of DILP2. These results might have parallels with
a role for FOXO and TOR in the regulation of insulin levels in
mammals.
We also see a selective and unexpected regulation of dTOR
effectors: loss of d4EBP protein and a mild effect on dS6K
Ser389 phosphorylation. It has been recently shown that the
d4EBP gene is a target of dFOXO inDrosophila (Bernal and Kim-
brell, 2000; Junger et al., 2003; Miron et al., 2001; Tettweiler
et al., 2005) and thus may represent one of the dTOR targets re-
sponsible for contributing to the dFOXO-mediated metabolic
phenotypes. It has also been shown that daf-15/Raptor is a tar-
get of daf-16/FOXO inC. elegans and may also contribute to the
dTOR metabolic and senescent phenotypes (Jia et al., 2004).
Raptor may also account for the selective difference in the reg-
ulation of d4EBP and dS6K function by TOR because Raptor
binds to both S6K and 4EBP and loss of 4EBP may allow for
more S6K binding to Raptor for TOR-mediated phosphorylation
(Hara et al., 2002). Thus, these results suggest that reduction of
dTOR function may have selective effects on translation.
TOR may control aging and organ senescence
as a caloric restriction mediator
Reduction of dTOR function does not provide resistance against
acute stresses or cause sterility. This result is in contrast to the
yeast TOR1 mutant, which shows elevated stress resistance
(Powers et al., 2006), and the d4EBP mutant, which shows
stress and starvation sensitivity (Tettweiler et al., 2005). Never-
theless, the dTOR7/P mutant has an increased lifespan. This
result is in keeping with the yeast, worm and fly studies that
show that loss of TOR signaling can increase lifespan, as amajor
mediator of caloric restriction (Kaeberlein et al., 2005; Kapahi
et al., 2004; Powers et al., 2006; Vellai et al., 2003). Thus, alter-
ations of TOR signaling contribute to the regulation of lifespan.
We also see that reduction of dTOR activity prevents age-
dependent functional decline of heart performance. It is not cur-
rently clear how dTOR is regulating these organ and organismal
responses, but the altered lipid metabolism may underlie these
changes. For example, changes in lipid metabolism can both
autonomously and non-autonomously affect heart function
(Belke et al., 2002; Chiu et al., 2005; Park et al., 2005). Thus,CELL METABOLISM : AUGUST 2006
TOR couples energy homeostasis to senescencereduction of dTOR function may reallocate energy stores prefer-
entially for the control of ‘long-term’ responses such as lifespan
and organ maintenance. Importantly, there are many potential
links between changes in energy homeostasis with alterations
in aging and organ senescence (Curtis et al., 2005; Kenyon,
2005; Wessells et al., 2004). Channelling diverse stimuli like
amino acids, growth factors, oxygen tension, and energy charge
into the TOR pathway may be an economic method to mobilize
fuel stores like lipids to counteract these fluctuations.
Drosophila is a model system to study metabolic
syndrome and diabetes
The conservation of basic mechanisms betweenDrosophila and
mammals is well established. It has been shown that disruption
of insulin signaling in non-mammalian systems like Drosophila
results in altered glucose and lipid levels (Broughton et al.,
2005; Rulifson et al., 2002). We found that reducing dTOR func-
tion can reverse activated dFOXO-mediated insulin resistance
phenotypes induced in both insulin producing and insulin receiv-
ing tissues, and thus this study provides the first direct evidence
that reducing TOR function may have a clinical benefit to
counter insulin resistance, metabolic syndrome, and/or diabe-
tes. Furthermore, altering TOR signaling may underlie the bene-
fits of various diet and nutritional regimens. These results dem-
onstrate the utility of using the powerful genetics of this system
to unravel the complex pathways involved in maintaining glu-
cose and lipid homeostasis. In unraveling the complex genetic
network of TOR and InR signaling, although far from completion,
the Drosophila model has been indispensable in finding critical
components and uncovering functionally important genetic in-
teractions between these two pathways (Oldham and Hafen,
2003). Thus, the basic mechanisms controlling glucose and lipid
homeostasis, including mechanisms by which the TSC1-2/TOR
pathway influences insulin signaling as well as the influence of
TSC1-2/TOR signaling on peripheral tissue and IPC physiology,
are also functionally conserved.
Conclusion
We have described a new use for reducing dTOR activity to
block insulin resistance, metabolic syndrome, and diabetic-
like phenotypes downstream of activated dFOXO, underlining
the utility of the Drosophila model to identify and analyze com-
ponents and compounds that block insulin resistance and met-
abolic syndrome phenotypes as well as pathological aspects of
aging and organ senescence.
Experimental procedures
Fly genetics
Standard genetic analyses were performed as described (Oldham et al.,
2000). A detailed description of the new dTOR allele will be described else-
where (unpublished data).
Immunohistochemistry, Western, and RT-PCR analyses
We used the DILP2 antibody to measure DILP2 protein levels by performing
immunohistochemistry as described (Rulifson et al., 2002) and wt-d4EBP,
phospho-4EBP, wt-dS6K, and phospho-dS6K antibodies to perform West-
ern blotting as described (Miron et al., 2001; Oldham et al., 2000).We isolated
total RNA (Qiagen) and constructed cDNA libraries (Stratagene) from the yw
control, dFOXO-TM, the dTOR7/P mutant, and combinations. We then per-
formed semiquantitative RT-PCR using primers that spanned the DILP2,
dFAS, or brummer intron and used actin5C as an internal loading control
(primer sequences and cycle conditions available upon request).CELL METABOLISM : AUGUST 2006Metabolic assays
Lipid and glucose
We isolated the fat body from third instar larvae, fixed them with formalde-
hyde, and stained them with 0.5 mg/ml (final) Nile Red. The fat body was
washed with 13 PBS and then mounted in Vectashield for fluorescence mi-
croscopy (Zeiss, Axiophot). Triglyceride and glucose levels were detected
using a glucose oxidase assay (Pointe) and lipid assay (Thermo) as described
(Rulifson et al., 2002; Teleman et al., 2005a) with exception that we extracted
the lipids with a 1:1 mixture of chloroform/methanol (vol:vol).
Ketone bodies
The b-hydroxybutyrate (bHB) ketone body was measured as follows: we
used 20 mg of tissue weighed on a balance cooled with cups of liquid N2
around the balance pan. The tissue was weighed into a 1.5 or 2.0 ml screw
cap Eppendorf centrifuge tube containing glass beads (1 mm diameter) that
was cooled in liquid N2. To the tissue, 4 volumes of ice-cold 0.55Mperchloric
acid were added and homogenized immediately for 30 s using a Minibead-
beater (Biospec Products). The samples were then neutralized by adding
3 M KHCO3. After neutralizing, the tubes were placed in ice 30 - 60 min
and spin and transferred the supernatant to a screw cap cent tube for anal-
ysis. For the fluorometric assay thewells contained: 50mM2-Amino-2-meth-
ylpropanol (pH 9.9), 5 mM NAD, 2 mM EDTA, 0.01% BSA. Analyses were
done using a TECAN Spectrafluor Plus microplate reader (Durham, NC)
using a 340 nm excitation filter and a 465 nm emission filter. We used
bHB dehydrogenase (Biocatalytic) and NADH production from bHB was
measured.
Stress, aging, and heart senescent assays
Starvation
Survival of male flies was tested under water-only starvation conditions as
described in (Oldham et al., 2000).
ROS resistance
Survival of male flies was tested during exposure to paraquat-induced oxida-
tive stress. Flies were exposed to 10 mM Pq in 1% sucrose and survival was
assessed after 48 hr.
Lifespan
Lifespan assays were performed by taking 15–20 flies per tube and turning to
a fresh tube every 2–3 days. The number of viable flies was scored at these
intervals.
Heart function
Cardiac failure rates in response to electrical pacing were measured accord-
ing to (Wessells et al., 2004).
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